Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of bevacizumab (Avastin) plus XELOX as first-line treatment for locally advanced or metastatic colorectal cancer
2007-004969-18Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), colon cancer and rectal cancer, sponsored by Roche. Primary endpoint: Progression-free survival. Started Nov 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on 2007-004969-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004969-18.